Authors
Loading...
Retrospective analysis shows HSCT enhances progression-free survival in T-cell lymphomas, indicating a viable option for poor prognosis cases.
Llorente‐Chávez et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: